Rheonix, Mayo Clinic Ink Pact to Evaluate Warfarin-Sensitivity Test
June 23, 2011
Rheonix, Mayo Clinic Ink Pact to Evaluate Warfarin-Sensitivity Test
The eventual goal of the partnership would be to port the validated assay onto Rheonix's fully automated, modular molecular testing platform, which is still under development but may reduce the complexity and cost of warfarin sensitivity testing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rheonix Wins $233K NIAID Grant to Add UTI Detection to Multiplex STD Molecular Dx
August 26, 2010 / PCR Insider - Rheonix Wins $500K NSF Grant to Develop Water-Testing App for CARD System
February 10, 2011 / PCR Insider - Study Vets Abbott Plex-ID Platform as Tool for Broad Fungal ID Directly from Clinical Specimens
March 28, 2013 / PCR Insider - People in the News: Rheonix, BioFire Diagnostics Name New Board Members
October 18, 2012 / PCR Insider - Mayo Clinic Licenses IP from Qiagen to Develop PCR Test for TB Speciation
July 19, 2011 / PCR Insider